Search Results

You are looking at 1 - 10 of 96 items for :

  • Haematology, Oncology x
Clear All
Open access

Adam A. Mieloch and Wiktoria M. Suchorska

References 1. Jones DL, Wagers AJ. No place like home: anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol 2008; 9: 11-21. 2. Tropepe V, Turksen K. The ontogeny of somatic stem cells. Stem Cell Rev 2012; 8: 548-50. 3. Moore K A, Lemischka IR. Stem cells and their niches. Science 2006; 311: 1880-5. 4. Turksen K. Adult stem cells and cardiac regeneration. Stem Cell Rev 2013; 9: 537-40. 5. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by

Open access

Marju Kase, Ave Minajeva, Kristi Niinepuu, Sandra Kase, Markus Vardja, Toomas Asser and Jana Jaal

; 97: 377-81. 6. Kase M, Vardja M, Lipping A, Asser T, Jaal J. Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme. Radiother Oncol 2011; 101: 127-31. 7. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the ‘microenvironment-stem cell unit’? Mol Oncol 2011; 5: 374-86. 8. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage

Open access

Neza Podergajs, Narve Brekka, Bernhard Radlwimmer, Christel Herold-Mende, Krishna M. Talasila, Katja Tiemann, Uros Rajcevic, Tamara T. Lah, Rolf Bjerkvig and Hrvoje Miletic

References 1. Stupp R, Mason WP, van den Bent, MJ, Weller M, Fisher B, Taphoorn MJ , et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 : 987-96. 2. Reya T, Morrison SJ, Clarke MF Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414 : 105-11. 3. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV , et al . Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012; 12 : 767

Open access

Matevz Skerget, Barbara Skopec, Darja Zontar and Peter Cernelc

Introduction Novel agents have significantly increased the response rate and overall survival (OS) of patients with multiple myeloma (MM), but high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are still considered the standard of care for younger patients. 1 - 5 Several mobilization regimens are currently used, most commonly growth factors alone or in combination with chemotherapy. Considering growth factors, the most commonly used are filgrastim (G-CSF) and the long acting pegfilgrastim. 6 - 8 The combination of

Open access

Güleser Saylam, Ömer Bayır, Salih Sinan Gültekin, Ferda Alparslan Pınarlı, Ünsal Han, Mehmet Hakan Korkmaz, Mehmet Eser Sancaktar, İlkan Tatar, Mustafa Fevzi Sargon and Emel Çadallı Tatar

) decreases levels of free oxygen radicals. Even though it seems to be a cytoprotective agent, amifostine has many adverse effects, limiting its widespread use. Pilocarpine is used for symptom relief, but none of the medications mentioned above have been advocated for prevention or symptomatic treatment of salivary gland damage. 5 - 10 However, to improve the patients’ quality of life and decrease the associated morbidities; new regenerative solutions are needed to obtain functional restoration and repair in affected tissues. Mesenchymal stem cells (MSCs) isolated from

Open access

Lucka Boltezar, Karlo Pintaric, Jože Pretnar, Maja Pohar Perme and Barbara Jezersek Novakovic

) in relapsed FL patients. 4 In a Cochrane review in 2012, the authors demonstrated that high dose treatment (HDT) with autologous stem cell transplantation (ASCT) improves the progressionfree survival in comparison with chemotherapy or immuno-chemotherapy in previously untreated patients with FL, but does not prolong the OS. 5 There is also evidence that HDT with ASCT brings benefits to patients with relapsed FL. 5 , 6 A consensus was made in 2013 by the European Group for Blood and Marrow Transplant stating that the SCT is appropriate in patients with first

Open access

Sebastian Giebel, Sylwia Oborska, Joanna Romejko-Jarosinska, Jarosław Dybko, Joanna Mańko, Joanna Sawczuk-Chabin, Agata Szymańska, Wojciech Legieć, Anna Czyż, Magdalena Maruszak, Maria Saduś-Wojciechowska, Joanna Drozd-Sokołowska, Paweł Steckiewicz, Anna Ejduk, Ewa Paszkiewicz-Kozik, Tomasz Ogórka, Michał Osowiecki, Łukasz Targoński and Michał Taszner

Background Autologous hematopoietic stem cell transplantation (autoHSCT) is widely applied for the treatment of patients with lymphoid malignancies [ 1 , 2 ]. Standard indications include multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). While in MM autoHSCT is used as consolidation of first line treatment, for most of lymphoma subtypes it is considered after failure of initial chemotherapy. Currently, autoHSCT procedures are almost exclusively performed using peripheral blood as a source of stem cells, which requires successful

Open access

Vera Kukaj, Shpresa Beqiri, Melihate Pushka, Myrvete Kabashi and Edmond Komoni

A case with myasthenia gravis, brain stem multiple infarcts, fracture of vertebrae Th6 and discal hernia to the Th7/Th8

Background. We report the case of a patient with myasthenia gravis accompanied with brain stem multiple infarcts, fracture of vertebrae Th6 and discal hernia of the Th7/TH8.

Case report. A 66-year-old male patient, one week prior to the hospitalization showed up complaints of dizziness, nausea, vomiting, numbness of the left side of the face, swallowing difficulty, left side body weakness, right side of the body numbness starting from the nipples and going down to the right leg as well as general fatigue. Six years ago the patient was diagnosed with myasthenia gravis based on electrophysiological investigations, pharmacologic tests and findings of acetylcholine (Ach) receptor antibodies in serum. He was then treated with the following medications: pyridostigmine of 60mg × 5/day, prednisolon of 20 mg (every other day), azathioprine 100mg tid. He was doing well under described therapy. Twenty years ago his left kidney was removed due to calculosis. He had also a sister that suffered of myasthenia gravis and diabetes mellitus.

Conclusions. Myasthenia gravis has a number of symptoms and signs which probaly are in common with stroke-including fatigue, muscle weakness, slurred speach and swallowing difficulty. The reported case supports the opinion that several medical conditions such as brain steam stroke may mimick myasthenia gravis.

Open access

Seyed Ardebili, Irena Zajc, Boris Gole, Benito Campos, Christel Herold-Mende, Sara Drmota and Tamara Lah

References Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 : 97-109. Pilkington GJ. Cancer stem cells in the mammalian central nervous system. Cell Prolif 2005; 38 : 423-33. Baur M, Preusser M, Piribauer M, Elandt K, Hassler M, Hudec M. Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single

Open access

Ana-Maria Moldovianu, Anca Popp, Zsofia Varady, Alina Tanase, Alexandra Marculescu, Camelia Dobrea, Didona Vasilache, Cerasela Jardan, Radu Niculescu and Daniel Coriu

immunosuppressive therapy or bone marrow transplantation as first-line therapy. 8. Lawler M, McCann SR, Marsh JC, et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br. J. Haematol. 2009;144(6):933-945. 9. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral